Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.826.044 €): Optimierung eines hochwirksamen Malaria-Impfstoffs von Plasmodium vivax Hor01.06.2023 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Optimierung eines hochwirksamen Malaria-Impfstoffs von Plasmodium vivax
Plasmodium vivax is the most widespread human malaria with 2.5 billion people living at risk in South America, Oceania and Asia. The revised Malaria Vaccine Technology Roadmap to 2030 recognises the severity of P. vivax malaria, calling for a vaccine intervention to achieve 75% efficacy over two years, now equally weighted with P. falciparum. However, if this ambition is to be realised, new and innovative approaches are urgently required to accelerate next-generation vaccine research and development, whilst the few known candidate antigens need to undergo early-phase clinical assessment. Here, we build on exciting breakthroughs in P. vivax vaccine research, recently pioneered in Europe, including new transgenic parasite technologies for functional assay development and production of a parasite clone that is safe for use in controlled human malaria infection (CHMI) clinical models. The Objectives of OptiViVax will now integrate ambitious multi-disciplinary scientific and clinical approaches around the parasite’s lifecycle and will use our increased knowledge of P. vivax immuno-biology to further develop next-generation vaccines with improved efficacy. We will diversify the portfolio of new antigens ready for clinical testing by reverse vaccinology and diversify their delivery with new platforms and adjuvants developed using sustainable and improved GMP bio-manufacturing know-how. In parallel, the efficacy of known leading antigens will be benchmarked for the first time using innovative design of clinical studies and CHMI models making these lead candidate vaccines ready for future field trials. Improved preclinical functional assays, using state-of-the-art transgenic parasite lines, will also allow for mechanisms of antibody-mediated protection to be deciphered. The availability of new functional assays and human challenge models will underpin the future framework for informed decision making by the clinical vaccine community, policy makers, funders and regulators.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| London School of Hygiene and Tropical Medicine Royal Charter | ? |
| Armauer Hansen Research Institute | 152.499 € |
| Fundacao Gimm - Gulbenkian Institute For Molecular Medicine | 496.471 € |
| Institut National de la Sante et de la Recherche Medicale | 500.000 € |
| Novavax AB | 11.100,00 € |
| Stichting Radboud Universitair Medisch Centrum | 2.214.438 € |
| University College Cork - National University of Ireland, Cork | 451.536 € |
Quelle: https://cordis.europa.eu/project/id/101080744
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: London School of Hygiene and Tropical Medicine, London, Großbritannien.